Life Stem Genetics
Life Stem Genetics Inc., a development stage company, focuses on establishing stem cell therapy based clinics worldwide. Its products and services include nutraceutical and medical supplements, and IV nutritional cocktails; stem cell banking services; stem cell treatments for degenerative conditions, hyperbaric oxygen therapy, cancer treatments, and weight loss; anti-aging stem cell therapy; anti… Read more
Life Stem Genetics (LIFS) - Net Assets
Latest net assets as of April 2014: $349.15K USD
Based on the latest financial reports, Life Stem Genetics (LIFS) has net assets worth $349.15K USD as of April 2014.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($566.90K) and total liabilities ($217.76K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $349.15K |
| % of Total Assets | 61.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Life Stem Genetics - Net Assets Trend (2012–2013)
This chart illustrates how Life Stem Genetics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Life Stem Genetics (2012–2013)
The table below shows the annual net assets of Life Stem Genetics from 2012 to 2013.
| Year | Net Assets | Change |
|---|---|---|
| 2013-07-31 | $-21.54K | -686.04% |
| 2012-07-31 | $3.67K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Life Stem Genetics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3876200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2013)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $69.61K | % |
| Total Equity | $-21.54K | 100.00% |
Life Stem Genetics Competitors by Market Cap
The table below lists competitors of Life Stem Genetics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Green Planet Grp
PINK:GNPG
|
$0.91 |
|
IFAN Financial Inc
PINK:IFAN
|
$0.91 |
|
Omni Ventures Inc
PINK:OMVE
|
$0.91 |
|
InfoSearch Media Inc
PINK:ISHM
|
$0.91 |
|
VisionGlobal Corporation
OTCGREY:VIZG
|
$0.91 |
|
Solar Enertech Corp
PINK:SOEN
|
$0.91 |
|
BOL Bancshares Inc. PFD
PINK:BOLBP
|
$0.91 |
|
Medical Connections Holdings Inc
OTCGREY:MCTH
|
$0.91 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Life Stem Genetics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2012 to 2013, total equity changed from 3,675 to -21,537, a change of -25,212 (-686.0%).
- Net loss of 38,762 reduced equity.
- Share repurchases of 13,550 reduced equity.
- Other factors increased equity by 27,100.
Equity Change Factors (2012 to 2013)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.76K | -179.98% |
| Share Repurchases | $13.55K | -62.91% |
| Other Changes | $27.10K | +125.83% |
| Total Change | $- | -686.04% |
Book Value vs Market Value Analysis
This analysis compares Life Stem Genetics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-07-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Life Stem Genetics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 2.12x | $-367.50 |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.61K |
Industry Comparison
This section compares Life Stem Genetics's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Life Stem Genetics (LIFS) | $349.15K | 0.00% | 0.62x | $0.91 |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |